Viro-immunological, clinical and psychosocial correlates of disease severity and long-term outcomes of infection in SARSCoV-2 - a prospective cohort study: *the VIS cohort study

*Viro-immunological, clinical and psychosocial correlates of disease severity and long-term outcomes of infection in SARSCoV-2 - a prospective cohort study*: *the VIS cohort study - The VIS Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56179

Enrollment

500

Registered

2020-05-08

Start date

2020-05-11

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona COVID19

Interventions

None listed

Eligibility

Age

16 Years to 99 Years

Inclusion criteria

Inclusion criteria: - informed consent documented by signature - age between 16 - 85 years - sufficient understanding of Dutch or English

Exclusion criteria

Exclusion criteria: - Unlikely to comply with the study procedures, as deemed by the recruiting research doctor/nurse - mental disorder that in the view of the investigator would interfere with adherence to the study procedures, or the decision to participate in the study. - Investigators or otherwise dependent persons - living in long term care facility

Design outcomes

Primary

Measure	Time frame
1: To identify socio-demographic, clinical, virological and/or host factors predictive of disease progression 2: To investigate the induction of lasting protective SARS-CoV-2-specific antibody (titers and breadth) and SARS-CoV-2-specific T cell responses (numbers and quality) in relation to disease severity, clinical recovery and patient characteristics or re-infection over time; 3: Asses the mid-term (4 weeks - 3 months post diagnosis) and long-term (until 2 year post diagnosis) sequelae of individuals who have experienced a SARS-CoV-2 infection, particularly with respect to respiratory function, socio-psychological outcomes and quality of life.	—

Measure

Time frame

1: To identify socio-demographic, clinical, virological and/or host factors predictive of disease progression 2: To investigate the induction of lasting protective SARS-CoV-2-specific antibody (titers and breadth) and SARS-CoV-2-specific T cell responses (numbers and quality) in relation to disease severity, clinical recovery and patient characteristics or re-infection over time; 3: Asses the mid-term (4 weeks - 3 months post diagnosis) and long-term (until 2 year post diagnosis) sequelae of individuals who have experienced a SARS-CoV-2 infection, particularly with respect to respiratory function, socio-psychological outcomes and quality of life.

—

Secondary

Measure	Time frame
(4) To gain insight in the immune response after vaccination 5: To investigate influenza vaccine responses in the context of waning immunity after prolonged absence of influenza circulation; 6: To establish a well characterised data-and biobank for future in-depth pathophysiological, immunological, host-genetic and further clinical and epidemiologic studies. Substudy objectives 7: To investigate risk factors (demographic, clinical, virological, immunological) for SARS-CoV-2 reinfections. 8: To understand which factors determine the longevity and breadth of protective SARS-CoV-2-specific humoral and cellular immunity. 9: To determine the health impact of SARS-CoV-2 reinfections or their sequelae.	—

Measure

Time frame

(4) To gain insight in the immune response after vaccination 5: To investigate influenza vaccine responses in the context of waning immunity after prolonged absence of influenza circulation; 6: To establish a well characterised data-and biobank for future in-depth pathophysiological, immunological, host-genetic and further clinical and epidemiologic studies. Substudy objectives 7: To investigate risk factors (demographic, clinical, virological, immunological) for SARS-CoV-2 reinfections. 8: To understand which factors determine the longevity and breadth of protective SARS-CoV-2-specific humoral and cellular immunity. 9: To determine the health impact of SARS-CoV-2 reinfections or their sequelae.

—

Countries

Netherlands

Outcome results